Grant ID

01T-047

Illness

Schizophrenia

Primary Drug/Intervention

Amantadine

Primary Dosage

100 mg b.i.d.

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Silver

Sample Size

29

Duration of Study Period for Each Subject

6 weeks

Outcome Measurements

PANSS, SANS, SAPS, Simpson-Angus, AIMS, Barnes Akathasia Cognitive Battery

Results

In the 29 patients who completed at least three weeks of the trial, amantadine was associated with improvement in visuomotor coordination in male patients at week 3 compared to baseline. Other measures of cognitive function and psychopathology were not significantly changed.

Publication

Silver H, Goodman C, Isakov V, Knoll G, Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int. Clin. Psychopharmacol. 2005 Nov; 20(6):319-26.

Link

http://www.ncbi.nlm.nih.gov/pubmed/16192841

PI Name

Henry Silver

Degree

MBBS

Center

Sha'ar Menashe Mental Health Center

Institution

Technion Research and Development Foundation

Address

City or Town

Technion City

State or Province

Haifa

Zip or Postal Code

32000

Country

Israel

Email Address

mdsilver@tx.technion.ac.il.